报价延迟最少15分钟:2026/07/19 11:29 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.54 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.58/-0.71
|
|
企业价值
285.24M
|
| 资产负债 |
|
每股账面净值
2.97
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Itis focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. |
